Sanara Medtech Inc (SMTI) FinancialsSMTIFinancialSanara Medtech Inc

Sanara Medtech Inc (SMTI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Soft tissue repair products, accounting for 89.7% of total sales, equivalent to $24.94M. Another important revenue stream is Bone fusion products. Understanding this composition is critical for investors evaluating how SMTI navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Sanara Medtech Inc maintains a gross margin of 90.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.33%, while the net margin is -1.46%. These profitability ratios, combined with a Return on Equity (ROE) of 23.72%, provide a clear picture of how effectively SMTI converts its operational activities into shareholder value.

In the context of the broader market, SMTI competes directly with industry leaders such as RCEL and OBIO. With a market capitalization of $313.77M, it holds a leading position in the sector. When comparing efficiency, SMTI's gross margin of 90.76% stands against RCEL's 82.17% and OBIO's 71.59%. Such benchmarking helps identify whether Sanara Medtech Inc is trading at a premium or discount relative to its financial performance.

Sanara reported a 19% revenue growth in Q1 2026, with gross margins at 90.76%, indicating strong operational efficiency. However, the company has faced net income losses in previous quarters, with a net income of -452,864 in Q2 2026.